These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22624832)

  • 1. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
    Kukreja RC; Salloum FN; Das A
    J Am Coll Cardiol; 2012 May; 59(22):1921-7. PubMed ID: 22624832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic GMP-dependent signaling in cardiac myocytes.
    Takimoto E
    Circ J; 2012; 76(8):1819-25. PubMed ID: 22785374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
    Kim GE; Kass DA
    Handb Exp Pharmacol; 2017; 243():249-269. PubMed ID: 27787716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
    Frankenreiter S; Groneberg D; Kuret A; Krieg T; Ruth P; Friebe A; Lukowski R
    Cardiovasc Res; 2018 May; 114(6):822-829. PubMed ID: 29438488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.
    Jackson EB; Mukhopadhyay S; Tulis DA
    Curr Vasc Pharmacol; 2007 Jan; 5(1):1-14. PubMed ID: 17266609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic guanosine monophosphate in the regulation of the cell function.
    Zbrojkiewicz M; Śliwiński L
    Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1276-1285. PubMed ID: 28026830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the nitric oxide/cyclic guanosine monophosphate pathway limited the cardioprotective effect of post-conditioning in hearts with apical myocardial infarction.
    Correa F; Buelna-Chontal M; Chagoya V; García-Rivas G; Vigueras RM; Pedraza-Chaverri J; García-Niño WR; Hernández-Pando R; León-Contreras JC; Zazueta C
    Eur J Pharmacol; 2015 Oct; 765():472-81. PubMed ID: 26387613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-5 inhibitors.
    Cockrill BA; Waxman AB
    Handb Exp Pharmacol; 2013; 218():229-55. PubMed ID: 24092343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets of cGMP/cGKI in Cardiac Myocytes.
    Adler J; Kuret A; Längst N; Lukowski R
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):494-507. PubMed ID: 32168155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts.
    Meier S; Andressen KW; Aronsen JM; Sjaastad I; Hougen K; Skomedal T; Osnes JB; Qvigstad E; Levy FO; Moltzau LR
    Eur J Pharmacol; 2017 Oct; 812():174-183. PubMed ID: 28697992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.
    Wang H; Kohr MJ; Traynham CJ; Ziolo MT
    J Mol Cell Cardiol; 2009 Aug; 47(2):304-14. PubMed ID: 19345227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes.
    Götz KR; Sprenger JU; Perera RK; Steinbrecher JH; Lehnart SE; Kuhn M; Gorelik J; Balligand JL; Nikolaev VO
    Circ Res; 2014 Apr; 114(8):1235-45. PubMed ID: 24599804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.
    Rainer PP; Kass DA
    Cardiovasc Res; 2016 Jul; 111(2):154-62. PubMed ID: 27297890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
    Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
    Ahmed WS; Geethakumari AM; Biswas KH
    Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.
    Mehel H; Emons J; Vettel C; Wittköpper K; Seppelt D; Dewenter M; Lutz S; Sossalla S; Maier LS; Lechêne P; Leroy J; Lefebvre F; Varin A; Eschenhagen T; Nattel S; Dobrev D; Zimmermann WH; Nikolaev VO; Vandecasteele G; Fischmeister R; El-Armouche A
    J Am Coll Cardiol; 2013 Oct; 62(17):1596-606. PubMed ID: 23810893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
    Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
    Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.